The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 798
Enfermedades pulmonares intersticiales
Serrano, M. P., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.010 · Cited by 2
Israni, A. K., Schladt, D., Bruin, M. J., Chu, S., Snyder, J. J., Hertz, M., Valapour, M., Kasiske, B. L., McKinney, W. T., & Schaffhausen, C. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004051 · Cited by 2
“Guidelines for selecting lung transplant candidates continue to evolve.(1,2) Selection criteria for candidates vary across programs because of many factors, including changing evidence and differences in practice.”
BackgroundSelf-citationLung Transplant as a Treatment for Patients with End-Stage Respiratory Failure Due to COVID-19
Urlik, M., Stącel, T., Latos, M., Pasek, P., Pióro, A., Zawadzki, F., Gmerek, M., Księżopolska, P., Przybyłowski, P., & Ochman, M. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.03.017 · Cited by 2
“It was also assessed that it is too early to make more conclusive recommendations now [21].”
Recipient Management before Lung Transplantation
Kim, H. S., & Park, S. (2022) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/jcs.22.042 · Cited by 2
“Severe osteoporosis is considered a relative contraindication to lung transplantation [5,38].”
BackgroundMethodInfluentialTeh, L., Henderson, D., Hage, C. A., et al. (2022) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2022.12.004 · Cited by 2
Long Term Survivors of Hematopoietic Stem Cell Transplantation: The Role of the Pulmonologist
Cheng, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-28797-8_37 · Cited by 2
Influence of De Novo Malignancies on Long-Term Survival after Lung Transplantation
Ruiz, E., Moreno, P., Gonzalez, F. J., et al. (2023) · Cancers · doi:10.3390/cancers15154011 · Cited by 2
“Patients were selected for lung transplantation after a multidisciplinary evaluation according to International Guidelines [10].”
MethodImaging Features of Autoimmune Disease-Related Interstitial Lung Diseases
Walsh, S. L. F., Lafyatis, R., & Cottin, V. (2023) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000734 · Cited by 2
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2023
Bhatt, H. V., Fritz, A. V., Feinman, J. W., Subramani, S., Malhotra, A. K., Townsley, M. M., Weiner, M. M., Sharma, A., Teixeira, M. T., Lee, J., et al. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.10.030 · Cited by 2
Future directions for xenotransplantation in lungs
Hara, H., Sahara, H., & Chen-Yoshikawa, T. F. (2024) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001161 · Cited by 2
Lung transplant referral considerations for individuals with cystic fibrosis
McLafferty, F. S., & Gray, A. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001111 · Cited by 2
Ozeki, T., Higo, H., Omori, H., Mori, S., Tanaka, S., Makimoto, G., Ninomiya, K., Taniguchi, A., Fujii, M., Miyoshi, K., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3854-24 · Cited by 2
“…of lung transplant candidates and often results in persistent pulmonary infection; however, several studies have shown that lung transplantation is feasible, especially in patients with Mycobacterium avium complex (MAC) lung disease (1-3), and NTM is not a contraindication in the guidelines (4).”
A Center Experience with Lung Transplantation for COVID-19 ARDSPreprint
Franco‐Palacios, D. J., Allenspach, L. L., Stagner, L. D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3997859 · Cited by 2
Ethical considerations in lung re-transplantation
Lester, L., Huang, V. P., Wightman, S. C., & Rosenberg, G. M. (2024) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001171 · Cited by 2
Bunel, V., Brioude, G., Deslée, G., Stelianides, S., & Mal, H. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.008 · Cited by 1
A Case Study of a Transplant Candidate With Stress-Induced Takotsubo Cardiomyopathy
Hoy, H. M., Black, N. M., & Trindade, A. J. (2023) · Progress in Transplantation · doi:10.1177/15269248231189871 · Cited by 1
“Evaluation for lung transplantation involves comprehensive assessment of organ function, psychosocial health, and risk for latent infections and malignancy.(1) This process can be stressful for a patient with advanced organ disease.”
BackgroundOptimizing the prelung transplant candidate
Pagteilan, J. N., & Atay, S. M. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001116 · Cited by 1
COPD - Pathology, Diagnosis, Treatment, and Future Directions
Jones, S. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001502 · Cited by 3
A Hospitable Home? Cell-Free DNA and the Inflammatory Milieu in Lung Transplant Candidates
Trindade, A. J. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2242ed · Cited by 1
“Current methods to select viable candidates focus on demographic characteristics, severity of gas-exchange abnormalities, extrapulmonary organ function, and exercise capacity (2).”
MethodAlbert, J. D., Daley, C. L., & Lin, P. L. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piae003 · Cited by 1
Sternal Elevation by Crane Technique During Double Lung Transplant for Patient With Pectus Excavatum
Binst, A., Jansen, Y. J. L., Ceulemans, L. J., et al. (2024) · Annals of Thoracic Surgery Short Reports · doi:10.1016/j.atssr.2024.02.001 · Cited by 1
Rozenberg, D., Andrawes, R. R., & Wentlandt, K. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001075 · Cited by 1
“modality for advanced lung disease that is known to improve health-related quality of life (HRQL), exercise tolerance, and survival [1 & ,2].”
BackgroundClinical Application of Frailty in the Evaluation of Solid Organ Transplant Patients
Cimeno, A., Madariaga, M. L. L., Basu, A., Pezzuto, D., Parsons, R. F., & Huisingh-Scheetz, M. J. (2024) · Current Transplantation Reports · doi:10.1007/s40472-024-00436-6 · Cited by 2
“%) of surviving for 5 years after transplantation [36].”
Gómez, A., Pascual, B. P., Launois, P., Blaya, V. P., Dávalos‐Yerovi, V., Berastegui-García, C., Esperidon-Navarro, C., Simon-Talero, C., Deu-Martin, M., Sacanell, J., et al. (2024) · Rehabilitación · doi:10.1016/j.rh.2024.100858 · Cited by 1
The foregut in cystic fibrosis
Vélez, C. D., Neuringer, I. P., & Schwarzenberg, S. J. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27123 · Cited by 1
“21 GRASP after LTx is a cofactor for CLAD, mediated through augmentation of alloimmune and non ‐ alloimmune injury to the graft, infection, and ultimately loss of lung function due to scarring of the terminal bronchioles.”
Outcomes of single-lung retransplantation after double-lung transplantation
Yin, V., Rodman, J., Atay, S. M., Wightman, S. C., Rosenberg, G. M., Udelsman, B. V., Ganesh, S., Chung, P., Kim, A. W., & Harano, T. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.09.039 · Cited by 1
Woo, W., Kim, H. S., Bharat, A., & Chae, Y. K. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100161 · Cited by 1
“The 2021 International Society for Heart and Lung Transplantation consensus has begun to acknowledge the potential eligibility of patients with pretransplant malignancy (pre-TM) for transplantation, 8 although the lack of robust evidence supporting these guidelines underscores ongoing uncertainty.”
Lessons Learned From Extracorporeal Life Support Practice and Outcomes During the COVID‐19 Pandemic
Gill, G., O’Connor, M. F., Nunnally, M., Combes, A., Harper, M. D., Baran, D. A., Avila, M., Pisani, B., Copeland, H., & Nurok, M. (2024) · Clinical Transplantation · doi:10.1111/ctr.15482 · Cited by 1
“In addition to established contraindications for lung transplantation, age greater than 65 years, concomitant organ dysfunction, restrictive lung disease, and repeat transplantation have been identified as risk factors in patients bridged to transplantation with ECMO [43, 45, 49–51].”
Chan, E. G., Deitz, R. L., Donohue, J. K., Ryan, J. P., Suzuki, Y., Furukawa, M., Noda, K., & Sánchez, P. G. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.10.041 · Cited by 1
Right Heart Recovery Post Lung Transplant With COVID‐19‐Related Acute Respiratory Distress Syndrome
Arunachalam, A., Toyoda, T., Nayak, T., Jankowski, M., Cerier, E. J., Kaiho, T., Joudi, A. M., Mohsin, S., Yeldandi, A. V., Subramani, M. V., et al. (2024) · Journal of Transplantation · doi:10.1155/2024/8483800 · Cited by 1
Kramer, A. H., Couillard, P. L., Doig, C., & Kromm, J. A. (2025) · Neurocritical Care · doi:10.1007/s12028-024-02204-x · Cited by 1
Is MUC5B rs35705950 promoter polymorphism associated with chronic lung allograft dysfunction?
Sandot, A., Ba, I., Massonnaud, C., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00006-2025 · Cited by 1
“Lung transplantation (LT) is a valuable therapeutic option, particularly for ILD [6].”
Cuesta, V. M. M., Zuazaga‐Fuentes, J., Fernandez, D. I., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70136 · Cited by 1
“The International Society for Heart and Lung Transplantation (ISHLT) periodically provides candidate selection recommendations to facilitate decision-making [5].”
InfluentialThe Use of Opioid Medications in Lung Transplant: A Scoping Review
Heyman, A. S., Punko, D., Meyer, F. L., et al. (2025) · Transplantation · doi:10.1097/tp.0000000000005343 · Cited by 1
GEORGAKOPOULOU, V. E. (2025) · World Journal of Transplantation · doi:10.5500/wjt.v15.i3.101866 · Cited by 1
Postoperative Lung Transplant Considerations in the Older Recipient
Hanna, S., Beermann, K. J., Levine, D. J., Loor, G., Singer, J. P., Smith, P. J., & Ali, H. A. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.10.060 · Cited by 1
Self-citationManagement of pharmacotherapy in lung transplant candidates
Rudzik, K. N., & Lyster, H. S. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001172 · Cited by 1
Ma, Y., Geng, Y., Wang, D., Wu, Z., Yang, X., Ma, L., Chang, R., Meng, B., & Zhu, Z. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.03.002 · Cited by 1
Outcomes of adult-to-adult living-donor lobar lung transplantation: A single institution experience
Nakajima, D., Sakanoue, I., Kayawake, H., et al. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.03.023 · Cited by 1
Considering candidates: modifiable and nonmodifiable risk factors for lung transplantation
Maheshwari, J. A., & Leard, L. E. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001174 · Cited by 1
“(ISHLT) for candidate selection, BMI 30 – 34.9 kg/ © m is considered a risk factor when assessing candidates for lung transplant, while BMI 35 kg/m is considered high risk [1] (Table 1).”
InfluentialSelf-citationAn Integrative Review of Frailty, Patient Mortality and Graft Failure in Solid Organ Transplant
Miller, T. L., & Russell, C. L. (2025) · Progress in Transplantation · doi:10.1177/15269248251343387 · Cited by 1
Orlitová, M., Demeulenaere, B., Beersel, D. V., Raemdonck, D. E. V., Vos, R., Ceulemans, L. J., Rex, S., Godinas, L., Verbelen, T., & Neyrinck, A. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100316 · Cited by 1
Bakinde, N., Johnson, A., Bakinde, D. N., et al. (2025) · Cureus · doi:10.7759/cureus.86412 · Cited by 1
“For patients with fibrosing ILD, disease progression can be non-linear, and delays in evaluation risk accumulating irreversible complications such as pulmonary hypertension, muscle wasting, or malnutrition, all of which may render a patient ineligible by the time access is secured [11].”
Decision-Making in Transplant Candidate Selection Committees
Kim, C. H., Lee, F. G., Beaman, L. R., Meyer, L. E., & Diwan, T. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.04.022 · Cited by 1
Oh, J. S., Rance, J. B., Choe, E. H., McWilliams, T. J., O’Carroll, M., Lewis, C. A., & Sithamparanathan, S. (2025) · Internal Medicine Journal · doi:10.1111/imj.70147 · Cited by 1
N1303K (p.Asn1303Lys) variant: Expanding frontiers in the treatment of cystic fibrosis
Pacheco, J., Almeida, L. M., Boaventura, R. D. P., Pereira, A. L., Rodrigues, C. S., Railean, V., Silva, I. A. L., Pankonien, I., Amaral, M. D., & Amorim, A. A. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108238 · Cited by 1
Stratifying GAP Stages by MUC5B rs35705950 T-Allele Carriage Refines Survival Prediction in IPF
van der Vis, J. J., Prasse, A., Renzoni, E. A., Stock, C. J. W., Maher, T. M., Bonella, F., Borie, R., Crestani, B., Wuyts, W. A., Molyneaux, P. L., et al. (2025) · Lung · doi:10.1007/s00408-025-00837-z · Cited by 1
“Lung transplantation remains the only curative treatment, a complex and invasive procedure requiring timely referral and careful patient selection, and is therefore reserved for a minority of patients with IPF [4, 5].”
Hui, D., Judd, A. C., Moneme, C., Passerini, H., Silpe, S., Podboy, A. J., Pelletier, S. J., Hallowell, P. T., & Shin, T. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165669 · Cited by 1
“Current consensus guidelines categorize lung transplant recipients with a BMI > 30 kg/m 2 as high-risk, and limited select specialized centers accept transplant candidates with a BMI > 35 kg/m 2 [118,119].”
Udagedara, M., Schwenger, K. J. P., Ghorbani, Y., Patel, T., Heusser, M., Zidar, D. J., Mak, J., & Allard, J. P. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.70027 · Cited by 1
“8,11 The protein catabolism is elevated after LTx leading to a higher negative nitrogen balance.”
Advancements in Pediatric Lung Transplantation
Ahmed, B., Spencer, H., & Brugha, R. E. (2025) · Respiratory The American Medical Journal · doi:10.33590/respiramj/htnq1062 · Cited by 1
Mental health and transplantation in cystic fibrosis
Georgiopoulos, A. M., Smith, B. A., Dellon, E. P., Hadjiliadis, D., Colman, R., Mullen, T. M. D., Quittner, A. L., & Sher, Y. I. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108407 · Cited by 1
Sarıbaş, E., Halis, A. N., Çitak, S., Kazan, A. M., Alkılıç, F. F., Vayvada, M., Çardak, M. E., & Taşçı, A. E. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2025.10.001 · Cited by 1
Tanyeri, S., Eminoğlu, H., Kültürsay, B., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70199 · Cited by 1
Vorstandlechner, M., Degenfelder, P. H., Yavuz, G., Glueck, O., Kovács, J., Walter, J., Dick, A., Michel, S. G., Schneider, C. P., Zöller, M., et al. (2025) · Transplant International · doi:10.3389/ti.2025.15350 · Cited by 1
Arike, L., Johansson, K., Ermund, A., Greer, M., Pelaseyed, T., Westin, J., Hansson, G. C., & Magnusson, J. M. (2025) · ERJ Open Research · doi:10.1183/23120541.00781-2025 · Cited by 1
“Lung transplantation (LTx) is a key treatment for end-stage, nonmalignant pulmonary disease when other treatments have failed [1].”
Lim, J., O’Brien, H., McCarthy, J., McCarthy, C., & Franciosi, A. N. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003520 · Cited by 1
“Third, the survey did not include open-ended questions, which may have limited the opportunity for respondents to elaborate on their views or highlight specific contextual or organisational factors influencing COPD management that are not captured by predefined response options.”
Lung transplantation for chronic thromboembolic pulmonary hypertension
Godinas, L., Orlitová, M., Muscogiuri, E., Ceulemans, L. J., Fadel, É., Delcroix, M., & Verbelen, T. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100461 · Cited by 1
“44,45 Consequently, it is essential to be able to assess survival in CTEPH patients.”
Frailty assessment and candidate optimization before cardiothoracic transplantation
Premachandra, A., Klapper, J. A., Messika, J., Gaillard, M., Kloëckner, M., Ghadimi, K., Reffienna, M., Ingle, K., Magudia, K. A., & Bottiger, B. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100492 · Cited by 2
“4–6 However, standardizing frailty measurement remains challenging due to heterogeneity in phenotypes, assessment tools, timing, and limitations in physical performance testing in end-stage cardiopulmonary patients.”
Zhang, D., Du, W., Qin, W., Li, B., li, P., Wang, X., & Chen, W. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/4521997 · Cited by 1
Konoeda, C., Toyokawa, G., Yamaguchi, M., et al. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100509 · Cited by 1
Jurica, J. M., Odish, M. F., Lin, C. M., Owens, R. L., Yi, C., Parrett, M., Kabadi, A. A., Leblanc, S. K. D., Roche, C. E., Yung, G., et al. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100518 · Cited by 1
“45 In our series, 50% of patients died after the decision to withdraw care based on lack of transplant eligibility, with the main contraindication to transplant being the inability to meet rehabilitation goals.”
Harper, L., Kiamanesh, O., Burak, K., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.01.002 · Cited by 2
Palleschi, A., Zanella, A., Sacchi, M., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.01.017 · Cited by 1
Idiopathic Pulmonary Fibrosis: An Overview
May, J., & Jenkins, G. R. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50844 · Cited by 1
Konoeda, C., Toyokawa, G., Yamaguchi, M., et al. (2026) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-026-02273-z · Cited by 1
“Sixth, we did not investigate the impact of the GNRI in relation to the decline in %FVC, which is an important factor for the timing of referral to LT institutions and listing for LT [13].”
Dhôte, T., Grenet, D., Reynaud‐Gaubert, M., Chatron, E., Renaud-Picard, B., Tissot, A., Macey, J., Murris, M., Bunel, V., Sermet‐Gaudelus, I., et al. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.03.003 · Cited by 1
Physical function in lung transplant recipients: Clinical implications and rehabilitation strategies
Andrawes, R. R., Nourouzpour, S., Orchanian‐Cheff, A., Camacho, E., Park, J., Shore, J., Sheikholeslami, K., Minuk, L., Wickerson, L. M., Munawar, M., et al. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101020 · Cited by 1
Korutla, L., Mineura, K., DeMarais, N., Liu, C. R., Burke, V., Bai, Y. Z., Habertheuer, A., Hameed, I., Terada, Y., Talapaneni, S., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.04.021 · Cited by 1
Zaiem, F., Muldiiarov, V., Roy, S. B., et al. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100588 · Cited by 1
Impact of recipient–donor risk matching on graft survival after lung transplantation
Olson, M. T., Arjuna, A., Shacker, M., Walia, R., Schaheen, L., Hashimi, A. S., Bremner, R. M., Smith, M. A., & Roy, S. B. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.05.007 · Cited by 1
Hirama, T., Nagao, M., Yamaguchi, M., Shundo, Y., Ui, M., Watanabe, T., Mukai, S., Ikushima, T., Kawasaki, T., Miyazaki, Y., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108773 · Cited by 1
To treat or not to treat: Pulmonary hypertension due to chronic lung disease
Ghamsari, F., & Damico, R. L. (2026) · Journal of Precision Respiratory Medicine · doi:10.2500/jprm.2026.9.260005 · Cited by 1
Lung Transplant for Refractory Lung-Limited Stage IV Non–Small Cell Lung Cancer
Bharat, A., Kurihara, C., Chung, L. I., Gao, R., Kim, S., Lung, K. C., Myers, C. N., Subramani, M. V., Wahidi, M. M., Abazeed, M. E., et al. (2026) · JAMA · doi:10.1001/jama.2026.8717 · Cited by 1
Anderson, M. R., Arcasoy, S. M., Benden, C., Budev, M. M., Cano, M., Chandra, K. M. L., Clancy, M. J., Diamond, J. M., Dimarakis, I., Dragnich, A. G., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.05.035 · Cited by 1
Self-citationResults of Lung Transplantations Among Cystic Fibrosis Patients: A Single-Center Study
Urlik, M., Stącel, T., Latos, M., Nęcki, M., Zawadzki, F., Pasek, P., Przybyłowski, P., & Ochman, M. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.056 · Cited by 1
Aktueller Stand der Transplantationsmedizin im Bereich Herz- und Lungentransplantation
Niehaus, H., Haverich, A., & Ius, F. (2022) · Die Anaesthesiologie · doi:10.1007/s00101-022-01179-8 · Cited by 1
Highlights del 55.° Congreso SEPAR
Meñaca, A. M., Herranz, E. B., Muñoz‐Esquerre, M., Marín‐Oto, M., Moyano, M. G., Cascón, J. A., & Alonso, T. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100216 · Cited by 1
Suivi partagé des patients transplantés pulmonaires
Dégot, T., Douvry, B., Falque, L., Bautin, N., Frachon, I., Mankikian, J., Pavec, J. L., & Picard, C. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.024 · Cited by 1
Magouliotis, D. E., Bos, S., Esendagli, D. R., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00671-2022 · Cited by 1
“[31].”
BackgroundInfluentialLung transplantation outcomes in underweight recipients: A single center experience
Abdulqawi, R., Saleh, R. A., Devol, E. B., Aldakhil, H., Saleh, W. N., Hashim, M. Y., Albogumi, E., Algwaiz, G., Khalid, M., & Mutairy, E. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15080 · Cited by 1
Chirurgie des alten Menschen – Thoraxchirurgie
Ehrsam, J. P., & Aigner, C. (2023) · Wiener klinisches Magazin · doi:10.1007/s00740-023-00497-w · Cited by 1
dos Reis, F. P., & Pêgo‐Fernandes, P. M. (2023) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2023.1414030423 · Cited by 1
Franco‐Palacios, D. J., Allenspach, L. L., Stagner, L. D., Bryce, K., Simanovski, J., & Nemeh, H. W. (2023) · OBM Transplantation · doi:10.21926/obm.transplant.2303193 · Cited by 1
Tanaka, S., Fujioka, S., Ikeda, T., et al. (2023) · JTCVS Techniques · doi:10.1016/j.xjtc.2023.07.005 · Cited by 1
“54 Discussion 55 Chest wall abnormality is considered a contraindication for lung transplantation in most 56 lung transplant centers.(1) Recently, this prevailing view has been challenged by some 57 groups, which reported a satisfactory outcome of simultaneous repair of pectus 58 excavatum with lung transplantation.”
BackgroundLaimoud, M. H., Alanazi, Z. M., Alahmadi, F. B., et al. (2023) · Case Reports in Cardiology · doi:10.1155/2023/4846338 · Cited by 1
“According to the recent consensus report of the International Society for Heart and Lung Transplantation (ISHLT), lung transplantation should be considered early in patients with PAH before the deterioration of cardiopulmonary functions to have enough time for appropriate evaluation and suitable donor selection [25].”
MethodDonor and Recipient Age in Interstitial Lung Disease: Types of Lung Transplant Survival Outcomes
Hanna, K., Calvelli, H. R., Kashem, M. A., Zhao, H., Cheng, K., Leotta, E., Yanagida, R., Shigemura, N., & Toyoda, Y. (2023) · Journal of Surgical Research · doi:10.1016/j.jss.2023.07.012 · Cited by 1
Validated Prognostic Scores to Predict Outcomes in ECLS-Bridged Patients to Lung Transplantation
Faccioli, E., Lorenzoni, G., Schneiter, D., Dell’Amore, A., Hillinger, S., Schiavon, M., Caviezel, C., Gregori, D., Rea, F., Opitz, I., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11609 · Cited by 2
“… 90% with high-fl ow levels and with non-invasive oxygenation devices, hemodynamic instability, and use of positive pressure ventilation that could lead to further lung injury and secondary organ dysfunctions) and it is mostly recommended in patients who have already been evaluated for LTx [1 – 4].”
BackgroundZajacová, A., Scaramozzino, M. U., Bellini, A., Purwar, P., Ricciardi, S., Migliore, M., Meloni, F., & Esendagli, D. R. (2023) · ERJ Open Research · doi:10.1183/23120541.00854-2023 · Cited by 1
“According to the 2021 ISHLT consensus on the selection of LuTx candidates, age between 65 and 70 years is considered to be a risk factor while age >70 years is a relative contraindication [40].”
MethodYanagisawa, A., Takimoto, T., Kurahara, Y., Tsuyuguchi, K., Yoshida, S., Hirose, M., Inoue, Y., & Arai, T. (2023) · Internal Medicine · doi:10.2169/internalmedicine.2847-23 · Cited by 1
“…infection is associated with a poor prognosis after transplantation (22), and according to the International Society for Heart and Lung Transplantation’s consensus document, MABS infection is a risk factor with a high or substantially increased risk in patients undergoing lung transplantation (23).”
BackgroundBeale, A. L., Safavi, S., & Granton, J. T. (2024) · Current Respiratory Medicine Reviews · doi:10.2174/011573398x269419231213095516 · Cited by 1
Milinic, T., & Ramos, K. J. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202311-944ed · Cited by 1
“Importantly, oxygen use is a consistent predictor of death and has been incorporated as an indication for transplantation referral (15, 16).”
BackgroundSelf-citationMcGarrigle, L., Norman, G., Hurst, H., & Todd, C. J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078561 · Cited by 1
“Although psychosocial, nutritional and physical impairments impact post-LTx outcomes (1), the clinical operationalisation of frailty measurement in LTx relates overwhelmingly to the physical domain (5,12,13).”
BackgroundInfluentialStącel, T., Sybila, P., Mędrala, A., Ochman, M., Nęcki, M., Pasek, P., Kegler, K., Przybyłowski, P., Hrapkowicz, T., Borowik, D., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.04.007 · Cited by 1
Interstitial lung disease in autoimmune diseases
Nagaraja, V., Mira-Avendano, I. C., Diaz-Arumir, A., et al. (2024) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2023.12.002 · Cited by 1
van Dinter, S. R., Arslan, T., Boerman, S., et al. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02865-x · Cited by 1
“We saw no indication for any additional lung resection as this would not resolve the PAA, and lung transplantation was deemed unfeasible with the patient’s age of 70 and comorbidities [11].”
BackgroundŠterclová, M., Doubková, M., Sýkorová, Ľ., Bartoš, V., Žůrková, M., Lošťáková, V., Mokošová, R., Plačková, M., Lacina, L., Cimrova, M., et al. (2024) · Pulmonary Medicine · doi:10.1155/2024/5918042 · Cited by 1
“The criteria used for the selection of lung transplant candidates after full pretransplant assessment followed the guidelines published in 1998, 2006, 2014, and 2021 [4 – 7].”
BackgroundMethodLung Transplant for Chronic Obstructive Pulmonary Disease
Swartz, K., Mansour, A., & Alsunaid, S. R. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1787560 · Cited by 1
Pre-transplant Anemia as a Marker of Short-term Outcomes in Lung Transplant Recipients
Trindade, A. J., Fortier, A. K., Tucker, W. D., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.06.007 · Cited by 1
Hypersensitivity Pneumonitis: An Interesting Case of Acute Shortness of Breath in a Young Patient
Rafique, M., Arslan, F., Khan, J., et al. (2024) · Cureus · doi:10.7759/cureus.68683 · Cited by 1
“According to the International Society of Heart and Lung Transplantation, individuals with HP should be referred for lung transplant evaluation soon to increase their chances of being eligible for listing [16].”
MethodThe Secondary Pulmonary Hypertension Diagnosis is Not Useful in Lung Allocation
Sonnick, M. A., Laothamatas, K., Furfaro, D. M., D’Ovidio, F., Lemaitre, P. H., Stanifer, B. P., Sonett, J. R., Shah, L., Robbins, H., Magda, G., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.08.025 · Cited by 1
Self-citation
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
